drug · antibody

TEZSPIRE

updated 5mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 6 investigational indications.

targets

Thymic stromal lymphopoietin

all catalysts(0)

nothing on the calendar yet

Trials studying TEZSPIRE

phase1A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjectsnot yet recruitingn=178

News(4)

AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become…
fiercebiotech · 27d ago
AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win
Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.
biospace · 1mo ago
New data could widen use of AstraZeneca, Amgen immune disease drug
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
biopharma_dive · 1mo ago
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion i…
biospace · 1mo ago

brand

TEZSPIRE

trade names

Tezspire

generic

TEZEPELUMAB-EKKO

MOA

12.1 Mechanism of Action Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2λ that binds to human TSLP with a dissociation constant of 15.8 pM and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in inflammatory cascades. Airway and mucosal inflammation are important components of the pathogenesis of asthma and CRSwNP. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes, ILC2 cells) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in airway and mucosal inflammation. Increased levels of TSLP mRNA and protein are found in the airways of patients with asthma as well as in nasal polyp tissue. Blocking TSLP with tezepelumab-ekko reduces biomarkers and cytokines associated with inflammation including blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13; however, the mechanism of tezepelumab-ekko action in asthma and CRSwNP has not been definitively established.

indication

1 INDICATIONS AND USAGE TEZSPIRE is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated: • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. ( 1.1 ) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 ) • for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) 1.1 Asthma TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. 1.2 Chronic Rhinosinusitis with Nasal Polyps TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(4)

AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD

With a detailed data drop that AstraZeneca’s R&D chief describes as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become…

fiercebiotech · 27d ago

AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis win

Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.

biospace · 1mo ago

New data could widen use of AstraZeneca, Amgen immune disease drug

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

biopharma_dive · 1mo ago

AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis

AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion i…

biospace · 1mo ago

TEZSPIRE

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TEZSPIRE

News(4)

Report a data issue

comments(0)

TEZSPIRE

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TEZSPIRE

News(4)

Report a data issue

comments(0)